Showing 5361-5370 of 5689 results for "".
- Topcon Unveils New Maestro Unlimited OCT System at VEE 2019https://modernod.com/news/topcon-to-present-new-solution-for-oct-and-data-management-at-vee-2019/2476407/Topcon showcased several innovative new offerings at the Vision Expo East (VEE) conference in New York City. Topcon unveiled the new Maestro Unlimited, which pairs the Maestro 3D OCT with the new Topcon Harmony, a web-based data management application that provides unlimited device connect
- Compulink Previews New User Interface for its Optometry SMART EHR at Vision Expo Easthttps://modernod.com/news/compulink-previews-new-user-interface-for-its-optometry-smart-ehr-at-vision-expo-east/2476404/Compulink Healthcare Solutions, the creator of Advantage SMART Practice, an all-in-one EHR and practice management solution powered by artificial intelligence (AI), previewed the new user interface for its Eyecare Advantage at Vision Expo this week. Designed by a team of usability experts,
- Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japanhttps://modernod.com/news/aerie-pharmaceuticals-initiates-netarsudil-ophthalmic-solution-phase-2-clinical-trial-in-japan/2476406/Aerie Pharmaceuticals announced the commencement of patient dosing in its phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsu
- Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 in Patients with Macular Edema Associated with RVOhttps://modernod.com/news/aerie-pharmaceuticals-initiates-phase-2-clinical-trial-of-ar-1105-in-patients-with-macular-edema-associated-with-rvo/2476401/Aerie Pharmaceuticals announced the commencement of patient dosing in a phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This phase 2 study (AR1105-CS201) will be conducted at appr
- 5% People Tested Positive at Free Initial Screenings for Glaucoma at Saifee Hospitalhttps://modernod.com/news/5-people-tested-positive-at-free-initial-screenings-for-glaucoma-at-saifee-hospital/2476400/Saifee Hospital, one of Mumbai’s leading multi-specialty hospitals, conducted almost 400 free eye check-ups for their visitors to observe World Glaucoma Week. The check-ups were conducted throughout the week and more than 20 people were detected to have high
- VisionCare Announces Regulatory Approval of the CentraSight Treatment Program in Australiahttps://modernod.com/news/visioncare-announces-regulatory-approval-of-the-centrasight-treatment-program-in-australia/2476395/VisionCare announced that the Australian Department of Health Therapeutic Goods Administration has issued a Therapeutic Goods Certificate to the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), approving it for the improvement of visual acuity in patients who are 55 years and older with b
- GenSight Biologics to Present 72-Week Data From the REVERSE Phase 3 Trial of GS010https://modernod.com/news/gensight-biologics-to-present-72-week-data-from-the-reverse-phase-3-trial-of-gs010/2476389/GenSight Biologics announced that the 72-week results from the REVERSE Phase 3 clinical trial of GS010 will be presented at the 45th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), which will be held in Las Vegas from March 16 to 21, 2019. The results will be presented b
- Alcon Acquires Fluid-Based IOL Maker PowerVisionhttps://modernod.com/news/alcon-announces-acquisition-of-powervision/2476387/Alcon announced that it has acquired PowerVision for $285 million plus regulatory and milestone payments starting in 2023. PowerVision’s lens design utilizes the eye’s natural accommodating response to transport fluid in the IOL. While most presbyopia-correcting IOLs use a mult
- Nicox Signs Agreement for Zerviate in China for Up to €17 Million in Milestone Payments Plus Royaltieshttps://modernod.com/news/nicox-signs-agreement-for-zerviate-in-china-for-up-to-e17-million-in-milestone-payments-plus-royalties/2476381/Nicox SA and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of all
- Ivantis Announces 24-Month Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-24-month-results-of-landmark-prospective-randomized-comparative-migs-clinical-trial/2476379/Ivantis, developer of the Hydrus Microstent, announced the 24-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study were presented by Thomas Samuelson, MD, President of the American Society of Cataract and Refracti